Overview
DNA Script is one of France’s most scientifically ambitious deep tech companies — a pioneering synthetic biology startup that has invented and commercialized the world’s first benchtop enzymatic DNA synthesizer. Founded in 2014 in Paris by CEO Xavier Godard and co-founders with backgrounds from École Polytechnique and Institut Pasteur, DNA Script has reengineered one of the most fundamental processes in modern biology: the on-demand synthesis of custom DNA sequences.
The company’s EXPLOIT technology platform uses enzymes (specifically terminal deoxynucleotidyl transferase, or TdT) to synthesize DNA rather than the conventional phosphoramidite chemistry that has dominated DNA synthesis for 40 years. This enzymatic approach operates in water at room temperature (versus toxic solvents and elevated temperatures in chemical synthesis), enables synthesis of longer sequences with fewer errors, and eliminates hazardous chemical waste — a combination that positions DNA Script as not only a better instrument manufacturer but a platform enabling a new generation of biological applications that chemical synthesis constrains.
The SYNTAX System — DNA Script’s benchtop DNA printing instrument, launched commercially in 2022 — allows biology laboratories to synthesize custom DNA oligonucleotides (up to 200 bases) on-demand in hours, rather than ordering from centralized synthesis facilities with 1-5 day lead times. For drug discovery laboratories, clinical genomics operations, and synthetic biology researchers, the ability to print exact DNA sequences on demand is transformative — the equivalent of moving from commercial print shops to desktop printers.
France 2030’s health biotech axis has supported DNA Script’s development as a French deep tech champion in synthetic biology — a field where France has strong research foundations (Institut Pasteur, CNRS, INRAE) and ambitions to build commercial leadership.
France 2030 Funding & Projects
Bpifrance deep tech funding: DNA Script has received support from Bpifrance through multiple instruments including early-stage grants (i-Lab, i-Nov competitions) and subsequent deep tech investment. Bpifrance was an investor in DNA Script’s early funding rounds, consistent with its role as the primary public venture capital arm for French deeptech companies that France 2030 designates as strategic.
France 2030 health biotech axis: DNA Script’s enzymatic synthesis technology is directly relevant to France 2030’s bioproduction and advanced therapies objectives. Custom DNA synthesis is a critical input for:
- mRNA vaccine and therapeutic development (mRNA sequences are designed using DNA templates)
- Gene therapy (AAV vectors require synthetic DNA components)
- CRISPR gene editing (guide RNA design requires custom DNA synthesis)
- Antibody discovery (phage display libraries require massively parallel DNA synthesis)
- Diagnostic assay development (PCR primers, hybridization probes)
All of these application areas are France 2030 priorities. DNA Script’s technology accelerates each of them.
International collaboration: DNA Script’s R&D team in Paris works with CNRS, INRAE, and Institut Curie on applications at the intersection of enzymatic synthesis and biological research. These academic partnerships receive ANR (Agence Nationale de la Recherche) funding that complements private investment in advancing the science.
Key Technology & Innovation
EXPLOIT enzymatic synthesis platform: The core innovation is using TdT enzyme (which naturally adds nucleotides to the end of a DNA strand) and engineering it to accept chemically protected nucleotides, add one at a time (the controlled extension step), then deprotect to allow the next nucleotide to be added. This controlled, step-by-step enzymatic process produces DNA sequences of defined composition and length — the same outcome as chemical phosphoramidite synthesis but through a fundamentally different mechanism.
The enzymatic approach’s advantages are:
- Longer sequences: Chemical synthesis quality degrades significantly beyond 100-150 bases; enzymatic synthesis can produce high-quality sequences of 200+ bases
- Aqueous chemistry: Water-based reactions eliminate the toxic acetonitrile and other solvents that make chemical DNA synthesis an environmental and safety challenge
- Higher accuracy: Enzymatic synthesis error rates can be lower than chemical synthesis for longer sequences
- Platform extensibility: Enzymatic approaches can be extended to RNA synthesis, modified nucleotides, and exotic bases that chemical synthesis struggles with
SYNTAX System instrument: The benchtop instrument integrates enzymatic synthesis chemistry with microfluidic delivery, thermal management, and software control into a format compatible with standard molecular biology laboratories. Each SYNTAX System can produce up to 96 different DNA sequences simultaneously in a single run — enabling researchers to produce a library of variants (for CRISPR guide RNA screening, antibody maturation, or promoter engineering) in a single session.
Post-synthesis quality control: DNA Script integrates mass spectrometry-based quality verification into its workflow, enabling users to confirm synthesized sequence identity without sending samples to external sequencing services.
Market Position
The DNA synthesis market is dominated by centralized commercial synthesis providers (IDT / Integrated DNA Technologies, Twist Bioscience, Genewiz/Azenta) that accept orders and ship synthesis products. This model works for routine applications but creates bottlenecks when researchers need rapid iteration — a fundamental constraint in fast-moving areas like CRISPR research, mRNA vaccine design, or antibody optimization.
DNA Script’s competitive positioning is not to replace centralized synthesis providers for bulk commodity oligonucleotides, but to enable on-site synthesis where synthesis cycle time is the bottleneck. The addressable market is the thousands of academic and biopharmaceutical laboratories where researchers wait days for DNA orders when they need same-day sequences to continue their work.
Key competitor: Bionano Genomics, Molecular Assemblies (US startup also pursuing enzymatic synthesis), and the emerging class of DNA synthesis startups (Evonetix, Nuclera). None has commercialized a benchtop instrument at the scale that DNA Script has achieved with the SYNTAX System.
Commercial Progress
The SYNTAX System was formally launched in 2022 at the JP Morgan Healthcare Conference — the most prominent annual biopharmaceutical investment event. Early adopters include pharmaceutical R&D laboratories (DNA Script has disclosed partnerships with multiple top-20 pharma companies, not all named publicly), academic genomics centers, and synthetic biology companies. The company has installed SYNTAX Systems at sites in the US, Europe, and Asia.
Revenue from instrument sales and consumables (the reagent cartridges required for each synthesis run — the “razor and blades” business model) is growing but the company remains in investment phase, spending heavily on R&D for next-generation synthesis capabilities and on sales/marketing for international commercial rollout.
Leadership
Xavier Godard (CEO) brings both scientific depth and commercial sensibility to DNA Script. His educational background (École Polytechnique, PhD in biophysics) combined with experience at McKinsey before founding DNA Script positions him to translate highly technical innovation into a compelling commercial value proposition. Godard has been the public face of DNA Script’s international expansion and has represented France’s synthetic biology sector in France 2030 policy discussions.
Financial Profile
| Metric | Value | Notes |
|---|---|---|
| Total raised | ~$220M+ | Through 2023 |
| Key investors | Coatue, Bpifrance, Illumina Ventures, M Ventures (Merck KGaA) | Strategic + financial |
| Employees | ~250 | Paris R&D + San Leandro CA commercial HQ |
| Stage | Commercial launch / scale-up | SYNTAX System in market since 2022 |
| Revenue | Pre-material (early commercial) | Not publicly disclosed |
| Listed | No (private) | IPO timing dependent on commercial scale |
Illumina Ventures and M Ventures (Merck KGaA) as strategic investors signal the DNA synthesis industry’s conviction that enzymatic synthesis is the next platform — these are sophisticated investors with deep commercial relationships across the life sciences tools market that Dataiku can leverage for commercial partnerships.
Investor Perspective
DNA Script is a high-risk/high-reward deep tech investment in a category that could become a standard laboratory instrument within a decade. The investment case rests on whether enzymatic synthesis can capture a meaningful share of the DNA synthesis market ($1.5B+ annually for custom oligos, growing 8-10% per year) and whether DNA Script’s SYNTAX System achieves the installed base density needed to generate durable consumables revenue.
The closest public market analog is the benchtop gene synthesis market opportunity that Twist Bioscience (TWST) represents at larger sequence scale — though Twist uses a different (array-based) synthesis technology and targets synthetic gene production rather than oligonucleotides. DNA Script’s nearer-term revenue model is consumables per synthesis run, similar to how sequencing companies (Illumina, Pacific Biosciences) generate recurring flow cell/chemistry revenue.
For France 2030 thematic exposure, DNA Script represents France’s ambition in synthetic biology — a field where the US leads commercially (IDT, Twist, Ginkgo Bioworks) but where France has genuine scientific foundations.